Form 4: AN2 Therapeutics CEO Eric Easom Reports Stock and Option Transactions
SEC Form 4
CEO Eric Easom reports acquisition of stock and options in AN2 Therapeutics, including restricted stock units and stock options vesting over four years.
Summary
- Eric Easom, CEO of AN2 Therapeutics, filed a Form 4 detailing changes in beneficial ownership.
- The report includes the acquisition of 145,250 shares of Common Stock and 290,500 stock options on February 26, 2025.
- The shares were acquired as restricted stock units (RSUs) and vest over four years from January 1, 2025.
- The stock options have an exercise price of $1.13 and also vest monthly over four years from January 1, 2025.
- Easom also indirectly owns shares through several trusts: the Easom Living Trust, the C. Easom Irrevocable Trust, and the Jude Easom Irrevocable Trust.
- Following the reported transactions, Easom directly owns 246,380 shares of Common Stock and 290,500 stock options.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a standard regulatory filing. The CEO acquiring shares and options could be seen as slightly positive, but it's not a strong indicator.
Positives
- The CEO's acquisition of stock and options could be interpreted as a positive signal, indicating confidence in the company's future performance.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. Investors often monitor these filings for signals about management's confidence in the company.
Stakeholder Impact
- The transactions could influence investor sentiment regarding AN2 Therapeutics.
Key Dates
| Date | Description |
|---|---|
| 2019-08-21 | Date of the Easom Living Trust |
| 2021-10-08 | Date of the C. Easom Irrevocable Trust and the Jude Easom Irrevocable Trust |
| 2024-01-01 | Start date for vesting of 99,000 RSUs |
| 2025-01-01 | Start date for vesting of 145,250 RSUs and stock options |
| 2025-02-26 | Date of the reported transactions |
| 2025-02-28 | Date of signature on the Form 4 |
| 2035-02-25 | Expiration date of the stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.